BioWorld

May 13, 2003

HGS Gains Exclusive License From Abgenix For CCR5 MAb

Human Genome Sciences Inc. exclusively licensed rights from Abgenix Inc. to develop a fully human monoclonal antibody to the CCR5 receptor, for which Abgenix earns an undisclosed milestone payment. (BioWorld Today) Read More

Genentech, XOMA Stop Trial In RA Because Of Lack Of Efficacy

Epimmune Enters Agreement For $13.5M Stock Merger With Anosys

Blue Heron Making Waves With Products For Gene Synthesis

BIO Asks Congress To Revisit Rule On Reimbursement Rates

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...